The abstract is read at the publisher; the summary is JClub's.
BVL3572S is bactericidal against Mycobacterium tuberculosis by covalently trapping PLP-dependent aminotransferases HisC and AlaA, depleting vitamin B6 cofactor.
- Why it matters: Rising multi-drug resistance in Mycobacterium tuberculosis creates a need for new antibiotics with novel mechanisms that can disrupt essential metabolism.
- What they did: The study mapped BVL3572S targets to HisC (Rv1600) and AlaA (Rv0337c) using X-ray crystallography showing a covalent PLP-BVL3572S adduct, plus isotopic labeling and CRISPRi/Tn-seq for pathway disruptions.
- The result: The PLP adduct formation and release indicate a futile cycle that perturbs amino acid biosynthesis and links to central metabolism, cell envelope integrity, and redox balance, with strong synergy versus D-cycloserine.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.